This approach may mitigate the risk of neuropathy associated with microtubule inhibitors.34 ILD is a significant risk for NSCLC patients treated with DXd-based ADCs.27,28,35 At the approved dose of 5.4 mg/kg for pretreated HER2-mutant NSCLC, the overall incidence of treatment-related ILD with T-DXd was 12.9% (grade ≥3, 2%; grade 5, n = 1).28 In the present study, 11.1% of 63 patients experienced ILD, with all cases being grade 1–2, except for one grade 5 case in the 6.4 mg/kg cohort. The gene discussed is ERBB2; the disease is non-small cell lung carcinoma.